Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Axcella Health (AXLA) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Axcella Health is one of 888 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AXLA is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for AXLA's full-year earnings has moved 46.62% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, AXLA has moved about 50.37% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -0.44% on a year-to-date basis. This means that Axcella Health is performing better than its sector in terms of year-to-date returns.
Looking more specifically, AXLA belongs to the Medical - Biomedical and Genetics industry, a group that includes 382 individual stocks and currently sits at #25 in the Zacks Industry Rank. On average, stocks in this group have gained 9.40% this year, meaning that AXLA is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track AXLA. The stock will be looking to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Axcella Health Inc. (AXLA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research